Richard Spalding – Startup Investor Profile

Richard Spalding, Managing Director at Kearny Venture Partners, focuses the investment thesis on healthcare products. The investment focus areas include medical devices and drugs in stages ranging from early to expansion. Kearny Venture Partners prefers collaborations in the healthcare sector, with previous investments in companies like Aerpio Therapeutics and Akebia Therapeutics. The investment check size typically ranges from $2-8 million for the first investment, going up to $10-15 million per company. Kearny Venture Partners emphasizes partnerships that drive growth and innovation in the healthcare industry.

Location: San Francisco, CA

Country: United States of America

Investment Regions: EU, NA

Investment Stages: pre-seed, seed

Website:

AI Reasoning: Tracxn and other public filings show Kearny Venture Partners’ most recent listed investment activity including Aerpio Therapeutics Series C on Mar 16, 2017 and portfolio companies; however, CVRx IPO had first invested May 11, 2006. The most recent specific investment by Kearny VP found is Mar 16, 2017 (Aerpio Therapeutics). Calculating time since last known investment to the target date indicates investments occurred more than 12 months ago. However, additional sources indicate portfolio activity and possible later acquisitions through 2018; no investments within last 12 months were found. Given uncertainty but evidence of investments within past 6-12 months is absent, classify as very-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.